These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1222395)

  • 41. 5-Fluorouracil (NSC-19893) compared to cyclophosphamide (NSC-26271) in bronchogenic carcinoma: results of a clinical study.
    Brugarolas A; Rivas A; Lacave AJ; Gonzalez-Palacois F; Froufe A
    Cancer Chemother Rep; 1975; 59(5):1025-6. PubMed ID: 1106844
    [No Abstract]   [Full Text] [Related]  

  • 42. Vindesine in bronchogenic carcinoma: a phase II trial.
    Vogelzang NJ; Peterson BA; Kennedy BJ; Vosika GJ; Conroy JA
    Am J Clin Oncol; 1982 Feb; 5(1):41-4. PubMed ID: 6282107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Evaluation of the results of chemotherapy in squamous cell bronchial carcinoma].
    Nagorni-Obradović L
    Med Pregl; 1991; 44(9-10):387-90. PubMed ID: 1806789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination chemotherapy for bronchogenic carcinoma with doxorubicin, BCNU, and cyclophosphamide (ABC): a pilot study of the Southeastern Cancer Study Group.
    Denes AE; Presant CA; Bartolucci A
    Cancer Treat Rep; 1982 Jan; 66(1):199-200. PubMed ID: 7053258
    [No Abstract]   [Full Text] [Related]  

  • 45. Chemotherapy in non-small cell bronchial carcinoma.
    Souhami R
    Thorax; 1985 Sep; 40(9):641-5. PubMed ID: 4060103
    [No Abstract]   [Full Text] [Related]  

  • 46. Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma.
    Creagan ET; Eagan RT; Fleming TR; Frytak S; Kvols LK; Ingle JN
    Cancer Treat Rep; 1979; 63(11-12):2105-6. PubMed ID: 230898
    [No Abstract]   [Full Text] [Related]  

  • 47. Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study.
    McGuire WP; Blough RR; Cobleigh MA; Johnson CM; Kukla LJ; Lad TE; Lanzotti VJ; Stiff PJ; Zawila P
    Cancer Treat Rep; 1983 Sep; 67(9):841-2. PubMed ID: 6883363
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical evaluation of procarbazine and fluorouracil in advanced lung cancer.
    Pacilio G; Puzziello T
    Bronches; 1971; 21(4):402. PubMed ID: 4340778
    [No Abstract]   [Full Text] [Related]  

  • 49. Chemotherapeutic management of bronchogenic carcinoma: trials with NSC-140117, a new methanesulfonic acid ester of aminoglycol.
    Gad-el-Mawia N; Mahmoud M; Osman A; El-Morsi B; El-Merzabani MM; Aboul-Enein M; Sakurai Y
    Cancer Chemother Rep; 1975; 59(2 Pt 1):367-70. PubMed ID: 167937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. cis-Dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma: a phase II study.
    Dombernowsky P; Sörenson S; Aisner J; Hansen HH
    Cancer Treat Rep; 1979 Apr; 63(4):543-5. PubMed ID: 221119
    [No Abstract]   [Full Text] [Related]  

  • 51. Chemotherapy of lung cancer: the experience of the National Cancer Institute of Milan.
    Bonadonna G; Tancini G; Bajetta E
    Cancer Chemother Rep 3; 1973 Mar; 4(2):231-7. PubMed ID: 4125741
    [No Abstract]   [Full Text] [Related]  

  • 52. Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma.
    Pisoni MB; Libretti A; Piazza E; Vago G; Scapaticci R; Bianchi C; Tomirotti M; Scanni A; Calzavara MP; Cassani L; Scarpazza G; Marsoni S; Morasca L
    Cancer Treat Rep; 1981; 65(7-8):731-2. PubMed ID: 6788372
    [No Abstract]   [Full Text] [Related]  

  • 53. [Photodynamic therapy of bronchial cancer].
    Häussinger K; Huber RM; Krug M; Breyer G; Baumgartner R; Beyer W; Jocham D; Stepp H; Unsöld E; Sroka R
    Pneumologie; 1990 Mar; 44(3):687-93. PubMed ID: 2326245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Phase II study of VP-16 in patients with primary bronchogenic carcinoma, with special reference to small cell carcinoma--a multi-institutional cooperative study].
    Kanda T; Oka M; Hara K; Koteda T; Ishizaki T; Ikebe A; Nakano M; Iwasaki H; Tsutsumi T; Okuno K
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):12-8. PubMed ID: 3009666
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase II clinical trial of diaziquone in bronchogenic carcinoma.
    Chiuten DF; Umsawasdi T; Dhingra HM; Murphy WK; Spitzer G; Carr DT; Bodey GP; Valdivieso M
    Cancer Treat Rep; 1985; 69(7-8):921-2. PubMed ID: 4016800
    [No Abstract]   [Full Text] [Related]  

  • 56. Hydroxyurea (NSC-32065) in therapy for nonresectable cancer of the lung.
    Kaung DT; Walsh WS; Sbar S; Patno ME
    Cancer Chemother Rep; 1968 Feb; 52(2):271-4. PubMed ID: 4869288
    [No Abstract]   [Full Text] [Related]  

  • 57. Preliminary clinical screening with daunorubicin in lung cancer.
    Kenis Y; Brulé G
    Eur J Cancer (1965); 1970 Apr; 6(2):155-6. PubMed ID: 5450194
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of hexamethylmelamine (NSC-13875) on small cell carcinoma of the lung (phase II study).
    Takita H; Didolkar MS
    Cancer Chemother Rep; 1974; 58(3):371-4. PubMed ID: 4601667
    [No Abstract]   [Full Text] [Related]  

  • 59. BCNU (NSC-409962) in the treatment of bronchogenic carcinoma.
    Whittington RM; Fairly JL; Majima H; Patno ME; Prentice R
    Cancer Chemother Rep; 1972 Dec; 56(6):739-43. PubMed ID: 4574055
    [No Abstract]   [Full Text] [Related]  

  • 60. High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium).
    De Jager R; Longeval E; Klastersky J
    Cancer Treat Rep; 1980; 64(12):1341-6. PubMed ID: 6258791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.